NASDAQ: EVOKEvoke Pharma Inc Stock
$1.66+0.04 (+2.47%)
Updated Jun 2, 2023
EVOK Price
$1.66
Fair Value Price
$4.11
Market Cap
$5.53M
52 Week Low
$1.37
52 Week High
$5.96
P/E
-0.66x
P/B
2.6x
P/S
2.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.90M
Earnings
-$8.29M
Gross Margin
86.3%
Operating Margin
-268.68%
Profit Margin
-285.9%
Debt to Equity
3.72
Operating Cash Flow
-$7M
Beta
0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EVOK Overview
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EVOK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVOK ($1.66) is undervalued by 59.75% relative to our estimate of its Fair Value price of $4.11 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EVOK ($1.66) is significantly undervalued by 59.75% relative to our estimate of its Fair Value price of $4.11 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EVOK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EVOK due diligence checks available for Premium users.
Be the first to know about important EVOK news, forecast changes, insider trades & much more!
EVOK News
Valuation
EVOK fair value
Fair Value of EVOK stock based on Discounted Cash Flow (DCF)
Price
$1.66
Fair Value
$4.11
Undervalued by
59.63%
EVOK ($1.66) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EVOK ($1.66) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EVOK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EVOK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.66x
Industry
14.9x
Market
52.74x
EVOK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.6x
Industry
1.79x
EVOK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EVOK's financial health
Profit margin
Revenue
$810.4k
Net Income
-$2.2M
Profit Margin
-276.8%
EVOK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EVOK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.0M
Liabilities
$7.9M
Debt to equity
3.72
EVOK's short-term assets ($9.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVOK's short-term assets ($9.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVOK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EVOK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
$0.0
Financing
$0.0
EVOK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EVOK vs Pharmaceutical Stocks
Evoke Pharma Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.